Document ID: chunk:federal_register_of_legislation:F2024L01389:schedule:1:p50
Version: federal_register_of_legislation:F2024L01389
Segment Type: schedule
Provision Reference: sch 1 (pt 50/66)
Character Range: 148030–152716

months of PBS and non-PBS-subsidised therapy; AND
                                                      Must be treated by a medical practitioner identifying as either: (i) a consultant physician, (ii) a general practitioner.
C16024  P16024  CN16024  Lanreotide                   Acromegaly                                                                                                                                                                                                                                                                                                                                                                                                          Compliance with Authority Required procedures - Streamlined Authority Code 16024
                                                      Initial treatment
                                                      Must be treated by a specialist practicing in a hospital who is either: (i) an endocrinologist, (ii) an oncologist; or
                                                      Must be treated by a medical practitioner working under the direct supervision of one of the above mentioned specialist types within a hospital setting; AND
                                                      The condition must be active; AND
                                                      Patient must have persistent elevation of mean growth hormone levels of greater than 2.5 micrograms per litre; AND
                                                      The treatment must be after failure of other therapy including dopamine agonists; or
                                                      The treatment must be as interim treatment while awaiting the effects of radiotherapy and where treatment with dopamine agonists has failed; or
                                                      The treatment must be in a patient who is unfit for or unwilling to undergo surgery and where radiotherapy is contraindicated; AND
                                                      The treatment must cease in a patient treated with radiotherapy if there is biochemical evidence of remission (normal IGF1) after lanreotide has been withdrawn for at least 4 weeks (8 weeks after the last dose); AND
                                                      The treatment must cease if IGF1 is not lower after 3 months of treatment; AND
                                                      The treatment must not be given concomitantly with PBS-subsidised pegvisomant.
                                                      In a patient treated with radiotherapy, lanreotide should be withdrawn every 2 years in the 10 years after radiotherapy for assessment of remission.
C16029  P16029  CN16029  Cefazolin                    Septicaemia, proven
                         Cefotaxime                   Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) an authorised PBS prescriber who is not a medical practitioner, but who is: (a) sharing care of the patient with at least one medical practitioner; (b) intending to share care of the patient with a medical practitioner.
                         Ceftriaxone
C16030  P16030  CN16030  Cefazolin                    Septicaemia, suspected
                         Cefotaxime                   Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) an authorised PBS prescriber who is not a medical practitioner, but who is: (a) sharing care of the patient with at least one medical practitioner; (b) intending to share care of the patient with a medical practitioner.
                         Ceftriaxone
C16034  P16034  CN16034  Fluconazole                  Fungal infection                                                                                                                                                                                                                                                                                                                                                                                                    Compliance with Authority Required procedures - Streamlined Authority Code 16034
                                                      The condition must be serious or life-threatening; AND
                                                      Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) an authorised PBS prescriber who is not a medical practitioner, but who is: (a) sharing care of the patient with at least one medical practitioner; (b) intending to share care of the patient with a medical